Novartis AG Net Income 2010-2022 | NVS

Novartis AG annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Novartis AG net income for the quarter ending March 31, 2022 was $2.222B, a 7.92% increase year-over-year.
  • Novartis AG net income for the twelve months ending March 31, 2022 was $24.184B, a 204.01% increase year-over-year.
  • Novartis AG annual net income for 2021 was $24.021B, a 197.58% increase from 2020.
  • Novartis AG annual net income for 2020 was $8.072B, a 31.2% decline from 2019.
  • Novartis AG annual net income for 2019 was $11.732B, a 6.97% decline from 2018.
Novartis AG Annual Net Income
(Millions of US $)
2021 $24,021
2020 $8,072
2019 $11,732
2018 $12,611
2017 $7,703
2016 $6,712
2015 $17,783
2014 $10,210
2013 $9,175
2012 $9,270
2011 $8,940
2010 $9,794
2009 $8,400
Novartis AG Quarterly Net Income
(Millions of US $)
2022-03-31 $2,222
2021-12-31 $16,308
2021-09-30 $2,758
2021-06-30 $2,896
2021-03-31 $2,059
2020-12-31 $2,094
2020-09-30 $1,935
2020-06-30 $1,867
2020-03-31 $2,176
2019-12-31 $1,125
2019-09-30 $2,042
2019-06-30 $6,799
2019-03-31 $1,766
2018-12-31 $1,195
2018-09-30 $1,623
2018-06-30 $7,768
2018-03-31 $2,025
2017-12-31 $1,976
2017-09-30 $2,081
2017-06-30 $1,980
2017-03-31 $1,666
2016-12-31 $957
2016-09-30 $1,940
2016-06-30 $1,804
2016-03-31 $2,011
2015-12-31 $1,054
2015-09-30 $1,888
2015-06-30 $1,836
2015-03-31 $13,005
2014-12-31 $1,491
2014-09-30 $3,223
2014-06-30 $2,555
2014-03-31 $2,941
2013-12-31 $2,029
2013-09-30 $2,232
2013-06-30 $2,516
2013-03-31 $2,398
2012-12-31 $1,985
2012-09-30 $2,390
2012-06-30 $2,648
2012-03-31 $2,247
2011-12-31 $1,002
2011-09-30 $2,464
2011-06-30 $2,704
2011-03-31 $2,770
2010-12-31 $2,169
2010-09-30 $2,275
2010-06-30 $2,417
2010-03-31 $2,933
2009-12-31 $2,305
2009-09-30 $2,098
2009-06-30 $2,035
2009-03-31 $1,962
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $200.009B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.705B 17.91
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
AbbVie (ABBV) United States $266.851B 11.70
Merck (MRK) United States $236.570B 13.36
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07